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The Role of CXCR3 in Breast Cancer Tumorigenesis caused by 
PyMT Cell Line 
 
Abstract: 
Breast cancer is responsible for the highest number of cancer related deaths in women 
each year. Recent breast cancer patient studies have shown that tumor cell expression of 
CXCR3, a chemokine receptor, results in poor overall survival. Conversely, another study shows 
that expression of CXCR3 on activated CD8 T cells enable migration to cancer sites, thereby 
contributing to tumor rejection. The purpose of this research is to determine whether or not 
CXCR3 plays a role in the tumorigenesis in a PyMT breast cancer mouse model. We examined 
the role of CXCR3 in breast cancer in vivo by infecting female CXCR3-/- and wild type mice with 
a Polyoma Middle T antigen (PyMT) breast cancer cell line. The immune response to the 
induction of tumorigenesis was examined through tumor measurements and FACS analysis of 
mouse tumors, spleens and lymph nodes. Initial findings indicate a significantly enhanced 
tumor growth in knockout mice, with knockout mice displaying tumor volumes three orders of 
magnitude greater than wild type mice. Further, the spleens and lymph nodes of CXCR3-/- mice 
contained lower numbers of infiltrating CD8+ T cells and CD4+ T cells and showed elevated 
numbers of alternatively activated macrophages (M2). In conclusion, our results demonstrate 
that CXCR3 plays a role in the immune response to tumorigenesis in a PyMT breast cancer 
mouse model. 
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Introduction: 
Breast cancer is a devastating disease responsible for many deaths of men and women 
throughout the nation. According to U.S. Breast Cancer Statistics, breast cancer death rates for 
women are higher than any other cancer besides lung cancer. Additionally, about 1 in 8 women 
will develop breast cancer in her lifetime (3). The immune system plays a major role in 
responding to cancer. Immune cells aggregate to the site of the tumor to defend against the 
tumor development.  
Research has shown that communication among various immune cells via chemokines is 
essential for leukocyte migration, metastasis, angiogenesis, and tumorigenesis (1). The CXCR3 
chemokine receptor has been shown to be associated with many types of cancer including 
breast cancer. CXCR3 is activated by three (IFN)-γ inducible ligands CXCL9, CXCL10, and CXCL11 
(2). CXCR3 is induced on naïve T lymphocytes after activation and is highly expressed on Th1 
associated T Helper lymphocytes, CD8 lymphocytes. Also, CXCR3 is present on cells of the 
innate immunity such as Natural Killer (NK), and Natural Killer T cells (NKT) (5). CXCR3 facilitates 
the migration of Th1 helper T cells and CD8 T cells to the tumor microenvironment allowing the 
lymphocytes to interact with antigen presenting cells, resulting in more effecter cells and 
memory cells (5). The Th1 response is known to suppress the tumorigenesis whereas the Th2 
response creates an environment permissive for tumorigenesis (5).  
While some research suggests that CXCR3 is beneficial when expressed on immune cells, 
other research shows that CXCR3 is expressed on tumor cells leading to poor prognosis. CRCX3 
promotes the growth of human glioblastoma multiforme (4). Additionally, Studies have shown 
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CXCR3 is expressed by tumor cells during melanoma, ovarian carcinoma, renal carcinoma, and 
breast cancer. (4). CXCR3 expression on cancer cells is correlated with poor patient prognosis. 
This indicates that CXCR3 has opposing effects when expressed on cells of the tumor 
microenvironment and when expressed on tumor cells. 
Little research has been published on the relationship between CXCR3 and breast 
cancer. Most studies focus on the metastasis of tumor cells expressing CXCR3 and use patient 
studies (10, 16). The focus of this research is to investigate the role of CXCR3 on lymphocytes, 
macrophages, and natural killer cells in breast cancer in vivo using a murine model. We 
hypothesize that CXCR3 is necessary for tumor suppression, and that knocking out CXCR3 will 
result in larger tumors in CXCR3 knockout mice than wild type mice.  
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Materials and Methods: 
PyMT Cell Line: 
The PyMT cell line was used to induce breast cancer in the mice. According to studies, the PyMT 
provides a realistic model of human breast cancer (6). The PyMT are comparable to human 
breast cancer in morphology and have four distinctly identifiable stages of tumor progression 
similar to human breast cancer. In addition, the expression of biomarkers in PyMT-induced 
tumors is also consistent with those associated with poor outcome in humans. (6) 
Mice/Infection:  
CXCR3 -/- and wild type female C57BL/6 mice were injected with 1 X 106/100 uL PyMT cells in 
their mammary gland. Sample mice included 5 WT and 5 CXCR3 -/- mice for Experiment 1 8 KO 
CXCR3 mice and 13 WT mice injected for Experiment 2.  
Tumor Measurements: 
Tumor volumes were measured every other day once the initial tumor developed. Tumor 
volume was calculated using the formula V = 0.52 X a2 X b, where (a) corresponds with the 
smallest superficial tumor diameter and (b) corresponds with the largest superficial tumor 
diameter. Mice were sacrificed after 62 days. 
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FACS Analysis: 
Fluorescence-activated cell-sorting (FACS) analysis was performed on single cell suspensions 
derived from tumor, spleen, and lymph node tissue harvested from every mouse injected with 
PyMT cells. The spleen and lymph nodes were examined because they play a major role in the 
immune system by filtering body fluid of foreign molecules. For macrophage specific staining, 
the single cell suspensions were incubated with anti-F4/80, anti-mannose receptor, anti-CD-
11b, and anti-IL-4 receptor alpha. For lymphocyte staining, cells were incubated with anti-CD3, 
anti-CD4, anti-CD8, and anti-NK1.1. Stained cells were analyzed with a FACS Caliber machine 
and results were analyzed with FlowJo software. 
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Results: Average Tumor Volumes 
  
 
 
 
 
 
The tumor volumes for experiment one were taken one week post infection and 
continued until day 49 when mice had to be sacrificed because tumor size exceeded the 
maximum volume regulation of 2 cm3. Superficial tumors were observed 7 days after injection 
for both wild type and CXCR3 KO mice however; the volumes decreased at week 4 for all of the 
wild type mice. One CXCR3 KO mouse continued growing a tumor until week 7 when the tumor 
became greater than the maximum volume regulation. The average tumor volumes of the KO 
mice were observed to have larger average tumor volumes than the average tumor volumes of 
the WT mice. 
                           
 
 
Figure 1A: The average tumor volumes for Experiment 1. 
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Results: Average Tumor Volumes 
 
 
 
 
 
 
  
During Experiment 2 the knockout mice started to differentiate from the wild type mice 
at four weeks post-injection. The initial measurements are only available three weeks post-
injection due to tumor visibility. There were 7 WT mice with tumors and 4 CXCR3 KO mice with 
tumors that were measured until the end point at 62 days post infection.  At 62 days tumors 
began necrotizing and exceeded the maximum regulation volume. Similarly to Experiment 1, 
the average tumor volumes for the CXCR3 KO mice were larger than the average tumor 
volumes for the WT mice.  
  
  
Figure 1B: The average tumor volumes for Experiment 2. Samples 
included. The tumors developed 
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Results: FACS Data Experiment 2  
 
 
 
 
 
 
  
      
     The FACS results for Experiment 2 examine the immune cells of the lymph nodes 
quantitatively. Figures 2A and 2B show the percentage of the lymphocytes that are present in 
the Lymph nodes of the mice. The Decrease in CD4 T lymphocytes shown Figure 2B between 
the CXCR3 KO and WT is statistically significant with P<0.05. There is also an observable 
decrease in the percentage of CD8 T lymphocytes however; this difference is not statistically 
significant.     
 
 
 
Figure 2A. Percentage of CD4+ T cells in the lymph nodes of KO and 
WT mice 62 days after PyMT cell injection. Control mice were not 
injected withPyMT cells. These percentages are from FACS analysis 
with gating on CD3+ and then CD4+, CD8– cells. 
 
Figure 2B. Percentage of CD8+ T cells in the lymph nodes of 
KO and WT mice 62 days after PyMT cell injection. Control 
mice were not injected with PyMT cells. These percentages 
are from FACS analysis with gating on CD3+ and then CD8+, 
CD4– cells. 
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Results: FACS Data Experiment 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
The FACS results for Experiment 2 examine the immune cells of the spleen 
quantitatively. Figures 3A and 3B show the percentage of the macrophages that are present in 
the spleens of the mice. The decrease in M2 alternatively activated macrophages in the CXCR3 
KO mice compared to the WT mice is statistically significant with P<0.05. There was no 
observable change in the classically activated M1 macrophages between the WT and CXCR3 KO 
groups.  
 
Figure 3A. The percentage of M1 macrophages 
in the spleen of KO CXCR3 and WT mice 62 
days after PyMT cell injection. Control mice 
were not injected with PyMT cells. These 
percentages were determined from gating on 
F4/80+, Mannose Receptor - cells. 
Figure 3B. The percentage of M2 macrophages 
in the spleen of KO and WT mice 62 days after 
PyMT cell injection. Control mice were not 
injected with PyMT cells. These percentages 
were determined from gating on F4/80+, 
Mannose Receptor+ cells. 
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Discussion: 
 The average tumor volumes and FACS analysis provide interesting clues as to CXCR3’s 
role in breast cancer tumorigenesis. CXCR3 knockout mice had lower average tumor volumes 
than the WT mice which was consistent with the initial hypothesis. The differences in 
tumorigenesis of the breast cancer are dependent on the type and action of immune cells 
present in the tumor environment. These cells create tumor environments by honing in 
immune effector cells via chemokines, secreting cytokines to induce a pro-inflammatory 
response, or honing in specific lymphocytes to suppress the pro-inflammatory immune 
response. 
 FACS analysis indicated that there was a fluctuation in the lymphocyte populations in 
the lymph nodes between the groups.  CXCR3 forms an inflammatory chemokine system 
capable of coordinating pro-inflammatory T lymphocyte responses in the periphery, making 
Th1 lymphocytes an integral part of the acquired anti-tumor immune response (5).  Results 
showed that KO mice had significantly lower CD4+ lymphocytes than the WT mice. The T helper 
lymphocytes also induce anti-tumor effects by coordinating the pro-inflammatory immune 
response (5). The decrease in the CD4+ lymphocytes in the CXCR3 KO mice could contribute to 
the observed increased tumor volume.   
Although not statistically relevant, FACS analysis data also showed that more CD8+ 
lymphocytes were present in WT mice lymph nodes compared to KO mice lymph nodes. 
According to patient studies of CD8+ lymphocytes in breast cancer, the more CD8+ T 
lymphocytes surrounding the tumor correlated to increased breast cancer survival (8,10). The 
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surrounding CD8+ cells are vital to the inflammation response and therefore anti-tumor 
immunity. CD8+ T cells can differentiate to become cytotoxic lymphocytes (CTLs), which secrete 
IFNγ along with other effector molecules providing a Th1 immune response (5). The CXCR3 is 
correlated to the Th1 type differentiation of lymphocytes. Furthermore, research has shown 
that CXCR3 is required on CD8+ cells for infiltration into the brain during cerebral malaria (9). 
CXCR3 KO mice were protected from cerebral malaria due to reduced CD8+ CTL entry into the 
brain. The CXCR3 is necessary for the CD8+ to gain entry into sites of inflammation (9).  
 Reduced CD8+ lymphocytes may be contributing to the increased tumor volumes of the 
CXCR3 KO mice in the PyMT model of breast cancer. The CXCR3 may be necessary for honing in 
the CD8+ lymphocytes. Investigation of the number of CD8+ lymphocytes in the tumor and 
surrounding the tumor would be necessary to make more solid conclusions.  The Th1 response 
is also regulated by the activation of macrophages present in the tumor microenvironment.  
Macrophages secrete cytokines and educate naive T lymphocytes into different effector 
T lymphocytes. We investigated the spleen to determine if the amount of macrophages 
fluctuated between the WT and CXCR3 KO mice. FACS analysis of macrophages shows that 
there was no fluctuation in the number of classically activated M1 macrophages in the spleen 
between the two groups of mice. This suggests that a Th1 pro-inflammatory response is 
occurring in both WT and CXCR3 KO mice. Th1 cytokines can trigger the formation of classically 
activated or M1 macrophages (11). The amount of M2’s fluctuated between groups. 
The number of M2 alternatively activated macrophages decreased in the CXCR3 KO 
mice without tumors compared to the WT mice however; The CXCR3 KO mice with tumors had 
an increase of M2 macrophages. The M2 are induced by cytokines such as:  IL-4, IL-10, TGF-β 
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and M-CSF (11). The M2 macrophages induce anti-inflammatory immune responses. Tumor-
associated macrophages have been shown to have M2 anti-inflammatory phenotypes (11). In 
human breast cancer, an increased amount of tumor-associated macrophage (TAM) correlates 
with poor patient prognosis. In mouse models of breast cancer, eliminating TAM’s from the 
tumor site results in less tumor progression (11). An increase in M2 may be contributing to 
larger tumors due to an anti-inflammatory effect on the tumor microenvironment. Results are 
contradictory between the mice with tumors and without tumors in the groups. Several mice 
from WT and KO groups were found to contain tumors in the peritoneal cavity making their 
tumor measurements impossible. Future studies will use isoflurane to anesthetize the mice 
creating a more uniform injection. More experiments will need to be conducted in order to 
make more conclusions concerning the M2 macrophage fluctuations between groups.  
In addition to improvements to future experiments, investigation into other subgroups 
of lymphocytes, tumor-induced myeloid –derived suppressor cell populations, and natural killer 
cells may provide further insight into role of CXCR3 in human breast cancer. Studies show that a 
decrease in CD4+CD25+ Regulatory T cells (T Regs) enhances cell-mediated anti-tumor 
immunity (15). Also, the depletion of T Regs was shown to stimulate the NK T cells (15). 
Research into the NK cells’ role in anti-tumor immunity has been performed with human breast 
cancer. Finding indicate that the dysfunction of NK cells results in human breast tumor 
progression (16). Lastly, research into myeloid-derived suppressor cell populations has provided 
data suggesting they are an important for the immune-evading mechanism used by tumors. 
These are heterogeneous populations of cells with diverse roles however; many have been 
shown to suppress T lymphocytes (17). 
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In conclusion, results indicate that CXCR3 plays a definite role in the tumorigenesis of 
breast cancer in the PyMT mouse model however; investigations into different anti-tumor 
associated immune cells and additional experimental trials are necessary for a clearer view of 
this role. Real-time PCR, along with western blots, may be helpful in determining what tumor 
related proteins are being produced and the various pathways of the immune cells.  The levels 
of proteins involved in angiogenesis, metastisis, and tumorigenesis may all be interesting in 
explaining the difference in tumor sizes between the CXCR3 KO and WT mice. Future research 
may lead to therapeutic advances in the clinical treatment of human breast cancer.           
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